Back to News
Market Impact: 0.25
Novartis' Phase 3 REMODEL Trials For Remibrutinib In Multiple Sclerosis Meet Primary Endpoint
Source: Nasdaq
Healthcare & BiotechClinical TrialsCompany FundamentalsProduct Launches
Novartis reported positive topline Phase 3 results for remibrutinib in adults with relapsing multiple sclerosis from the REMODEL-1 and REMODEL-2 trials. While specific efficacy/safety figures were not provided in the snippet, the Phase 3 readout is an upside catalyst for the program’s development outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVS0.65
More News
- ‘I told you so’: China’s chip sector is making breakthroughs—and U.S. export controls are the reasons why
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- EU Seeks New Trade Powers to Cut Trade Deficit